Gibson Oncology LLC and Purdue Research Foundation have synthesized DNA topoisomerase I (Topo1) inhibitors and/or Myc proto-oncogene protein promoter G-quadruplex (MycG4) ligands reported to be useful for the treatment of cancer.
Cytokinetics Inc. has identified bicyclic piperazinones with the ability to modulate skeletal muscle contractility reported to be useful for the treatment of amyotrophic lateral sclerosis, spinal muscular atrophy, myasthenia gravis, chronic obstructive pulmonary disease, stress urinary incontinence, sarcopenia, obesity and peripheral vascular disease, among others.
Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have synthesized radiolabeled compounds acting as GABA(A) receptor subunit α2β2γ1 (GABRA2) positive allosteric modulators acting as positron-emission tomography (PET) and autoradiography imaging agents reported to be useful for the diagnosis of neurological disorders.
Researchers at the University of California, Davis (UC Davis) have developed a method of biofluid assessment capable of real-time monitoring as well as compatible with machine learning and neural network processing.
Shanghai Institute of Organic Chemistry has described oleanamide derivatives acting as Kelch-like ECH-associated protein 1 (KEAP1)/nuclear factor erythroid 2-related factor 2 (NFE2-related factor 2; NFE2L2; NRF2)/antioxidant response element (ARE) pathway activators reported to be useful for the treatment of amyotrophic lateral sclerosis, diabetes, multiple sclerosis, renal disorders, Huntington's disease, Parkinson's disease, autoimmune disease and Alzheimer's disease, among others.